"Designing Growth Strategies is in our DNA"
Behcets Disease, also alternatively known as Behcet’s Syndrome, refers to a rare disorder that causes the inflammation of blood vessels throughout the body. One of the characteristics of the disease includes the occurrence of signs and symptoms which initially seem unrelated to one another. Some of the symptoms include inflammation of the eyes, mouth sores, genital sores, skin rashes, and lesions. Other affected areas of the body include the brain, the digestive system, and the joints. Behcet’s Disease is considered to be an autoimmune disease and genetic and environmental factors are considered to play a role in the occurrence of the disease.
Some of the diagnostic tools for Behcet’s Disease include blood tests and a pathergy test. For the treatment of Behcet’s Disease, an approach is undertaken where the individual symptoms are treated specifically. For instance, skin creams, gels, and ointments are used for skin and genital sores, mouth rinses are used for mouth sores and eye drops are used for the inflammation of the eyes. Systemic treatments such as corticosteroids for the controlling of the inflammation and medications that suppress or alter the immune system are administered.
Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for Behcet’s Disease. For instance; Apremilast (CC-10004), which is being studied by CELGENE CORPORATION, is currently in phase-3 clinical trials for A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Active Behcet's Disease.
To know how our report can help streamline your business, Speak to Analyst
At present, more than 80% of the pipeline candidates for Behcet’s Disease are in the phase-2 and phase-3 stage combined. Majority of the studies are sponsored by industry.
The report on ‘Behcet’s Disease – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Behcet’s Disease. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Behcet’s Disease.
The report on ‘Behcet’s Disease – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.